Brett Pollard is a Senior Managing Director at FTI Consulting and is based in London. Brett is in the Strategic Communications segment and part of the life sciences team.
Brett joined FTI Consulting in June 2015 from Abingdon Health where he was latterly Chief Operating Officer. He has been active in the healthcare industry for over 18 years, initially as an equity research analyst, and has extensive corporate development and executive level experience. Whilst at Abingdon Health, an in vitro diagnostics company, in addition to his operational responsibilities, Brett completed a number of company acquisitions and product development licensing transactions. In 2010, Brett established an IP commercialisation joint venture company, Bioscience Ventures, between Abingdon Health and the University of Birmingham which formed, financed and managed three independent commercial and development stage companies utilising university developed IP.
Before co-founding Abingdon Health Ltd in 2008 he was Head of Life Science Research at Numis where he led the team to Number 2 in the 2007 Extel. Sectors covered included biotech, pharma, healthcare services, diagnostic and medical devices. Brett has also spent time at Seymour-Pierce and Deutsche Bank in corporate finance. Brett has a PhD in Molecular Virology and a BSc in Cell and Molecular Biology, both from St. Andrews University. At FTI Brett has advised on equity story development, IPO and secondary issues, cross border M&A, crisis management and issue preparedness. Current clients include Abcam, Allied Minds, Mediclinic, Mereo BioPharma, NMC, Syncona, Tissue Regenix, Scapa and Zambon.